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Successful percutaneous mechanical circulatory support (MCS) has been used for 
acute stabilization of cardiogenic shock (CS). Improved survival outcomes have 
been observed in patients with CS from an acute myocardial infarction (AMI) who 
undergo implantation of left ventricular (LV) to ascending aorta rotodynamic 
pumps, such as the Impella® device (Abiomed). However, thrombotic events are a 
known complication of such devices in poor flow states such as CS. There is 
limited evidence regarding the management of patients who develop an LV 
thrombus after Impella insertion. Currently, the Sentinel cerebral protection system 
(SCPS, Boston Scientific) is the only FDA-approved device for cerebral embolic 
protection during transcatheter aortic valve replacement procedures. While the use 
of a cerebral embolic protection device (CEPD) has a theoretical benefit, no 
current CEPD is approved for use in conjunction with Impella device removal or 
other MCS devices. We present a case describing the use of the SCPS during the 
removal of the Impella CP device in a patient who developed an LV thrombus after 
CS from AMI. Our case highlights a potential role for the expanded use of CEPDs 
in similar clinical scenarios. 
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Background 
Several forms of percutaneous mechanical circulatory support (MCS) exist and 
include counterpulsation devices (intra-aortic balloon pumps) and continuous-flow 
devices. MCS also includes axial flow devices (Impella [Abiomed]) to advanced 
centrifugal flow devices (TandemHeart [LivaNova]) and veno-arterial 
extracorporeal membrane oxygenation (V-A ECMO). Device selection is 
dependent on several factors, and the potential complications vary from one 
device platform to another. The use of Impella is contraindicated in patients with 
known left ventricular (LV) thrombus due to the increased risk of 
thromboembolism.1 There is an obvious challenge to minimize the risk of embolic 
events in patients with LV thrombus that form after Impella implantation. To the 
best of our knowledge, literature addressing such a dilemma is scarce. We, 
therefore, highlight such a case to share our experience with off-label use of the 
Sentinal cerebral protection system (SCPS, Boston Scientific) to minimize embolic 
adverse outcomes.  
 
Case Report 
A 47-year-old male with no known medical history presented with two days of 
dyspnea on exertion and typical chest pain. On arrival, electrocardiogram was 
significant for anterior ST-elevation myocardial infarction (Figure 1).  
 
Figure 1. Presenting electrocardiogram shows ST elevation and Q waves in 
precordial leads. 
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The patient was promptly taken to the cardiac catheterization lab. Emergent 
bedside transthoracic echocardiogram (TTE) was significant for severely reduced 
LV systolic function with an ejection fraction of < 20% and global hypokinesis 
(Figure 2A & B). Left heart catheterization revealed severe two-vessel disease with 
subtotal occlusion of the left anterior descending artery and mid-right coronary 
artery along with significant left main coronary artery  disease. Hemodynamics 
(Table 1) were significant for left ventricular end diastolic pressure (LVEDP) at 
approximately 50 mmHg, along with elevated filling pressures.  
 
Figure 2. A) This is an Apical 4 chamber view of transthoracic echocardiogram 
(TTE) before deployment of the Impella CP. No left ventricular (LV) thrombus is 
seen. B) Definity® ultrasound contrast is used in this view and again demonstrates 
absence of LV thrombus. C) The tip of the Impella (white arrow) and apical mobile 
LV thrombus (red arrow) are identified. D) This is a close up image of the LV 
thrombus and tip of Impella. E) This TTE is 48 hours after Impella removal and F) 
is the same image with Definity ultrasound contrast. There was a similar finding six 
days post-Impella removal prior to discharge. 
 
Table 1. Hemodynamics. Pressures were attained from transthoracic 
echocardiogram and right heart catheterization. The cardiac output and index were 
calculated by the Fick calculation. 
Measure Value Upon Presentation 
Left ventricular end diastolic pressure ~50 mmHg 
Right atrial pressure 21 mmHg 
Right ventricular pressure 61/21 mmHg 
Pulmonary arterial systolic pressure/pulmonary 
artierial diastolic pressure 
61/44 mmHg 
Mean pulmonary arterial pressure 53 mmHg 
Pulmonary capillary wedge pressure 42 mmHg 
Cardiac output 2.39 L/min 
Cardiac index 1.4 L/min/m2 
 
The VAD Journal:  Impella removal in LV thrombus setting Page 4 of 7 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
Emergent bedside echocardiogram done in the cath lab with DEFINITY® 
ultrasound contrast (Lantheus) showed no evidence of LV thrombus. Given the 
clinical picture of acute myocardial infarction complicated by CS, the decision was 
made to stabilize the patient with MCS, using an Impella CP and to undergo 
emergent surgery with coronary artery bypass grafting (CABG). Unfortunately, the 
bypass surgery was complicated by circulatory collapse attributed to a protamine 
reaction which required emergent cannulation for VA-ECMO with average flow of 3 
L/min. 48 hours after Impella implantation and post-CABG, a TTE was significant 
for a 2.6 x 0.5 cm size mobile thrombus in the LV apex (Figure 2C, D). Initially 
heparin was used for anticoagulation; however, due to progressive 
thrombocytopenia and concern for heparin indicued thrombocytopenia (HIT), 
anticoagulation therapy was switched to argatroban. The combination of inotropes 
and MCS as well as volume optimization with intravenous diuresis, resulted in 
clinical improvement. The patient was able to be decannulated from V-A ECMO 
after three days. He continued to improve, and after approximately five more days 
of Impella support, the device was decreased to lower performance levels using 
inotropes and medical management to stabilize him. Given the interval 
development of his LV thrombus, and to reduce the risk of any catastrophic 
cerebral events in a young patient with no current neurologic deficits, the heart 
team (interventional cardiologists, cardiovascular surgeons, heart failure 
specialists) decided to remove the Impella in a hybrid operating room setting with 
the presence of vascular surgery and interventional cardiology teams. The 
multidisciplinary team was needed in part due to the need for immediate femoral 
artery hemostasis after Impella is removed. The extraction of the 14 French sheath 
while the patient remained on active anticoagulation with argatroban for LV 
thrombus and HIT represented a significant risk. We elected to utilize the SCPS to 
minimize the risk of cerebral embolization during the Impella removal procedure 
(Figure 3).  
SCPS was deployed via the right radial artery catherization prior to the Impella 
removal, which was performed via a femoral artery cutdown by the vascular 
surgeons. Once a femoral artery window with good visualization of the Impella 
insertion site and encircled vessel loops were established around the 
arteriorotomy, support was decreased from performance level 4 to level 2. The 
Impella was then removed and swift hemostasis was achieved with vessel clamps 
and interrupted 5-0 prolene suturing. Prior to closure, a thrombus was noted on the 
femoral artery posterior wall, which was removed and irrigated. A soft clot was also 
found in the Impella blood outlet area (Figure 4). The SCPS was then removed, 
and radial artery hemostasis was achieved via a TR band® (Terumo). There were 
no post-procedure complications. TTE after Impella removal showed the same, 
large (2.6 x 0.5 cm), mobile thrombus attached to the LV apex (Figure 2E, F). 
During recovery, the patient did well; no neurologic symptoms or deficits were 
noted. The patient experienced complete resolution of his initial presenting 
symptom of chest pain. He was discharged on warfarin, insulin for newly 
diagnosed diabetes mellitus, and guideline-directed medical therapy for new onset 
heart failure and coronary artery disease with cardiology follow-up. 
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Figure 3: Sentinel cerebral protection device deployment during Impella removal. 
A: Prior to Impella removal with deployment of left carotid artery (black arrow) and 
right brachiocephalic artery (white arrow) Sentinel filters were introduced via right 
radial access. Distal Impella CP pump near blood outlet area appreciated (red 
arrow) and pulmonary artery catheter (*). B: Impella removed via right femoral 
artery cutdown with both filters in place (arrows). Subsequent retrieval of left 
carotid filter (C) and right brachiocephalic filter (D). 
Figure 4: This is the Impella CP (Abiomed) device after removal. A soft clot is 
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Discussion 
Our case demonstrates several clinical dilemmas that physicians often face in CS 
patients supported by percutaneous MCS. Our patient’s clinical presentation was 
significant for CS including severely elevated LVEDP with acute respiratory failure 
and pulmonary edema from his acute MI (Table 1). The Impella CP (Performace 
level 4 and 2 L/min flow) was sufficient to unload his severely hypokinetic LV and 
provide adequate hemodynamic support until revascularization with CABG. 
However, due to circulatory collapse from protamine use during CABG, our patient 
required emergent extracorporeal life support with V-A ECMO. This event resulted 
in further myocardial stunning in an already poorly contracting LV. The resultant 
turbulent blood flow within the LV cavity and potential stasis significantly increased 
the risk of developing an intra-cardiac thrombus.2 Despite adequate 
anticoagulation, the risk of intra- or extra-cardiac thrombus formation is reported to 
be 3.9% in patients with impaired LV function who undergo femoral V-A ECMO 
with LV unloading.3 
Concomitant use of V-A ECMO and Impella is an often-used technique to vent the 
failing LV. By offloading the LV, the Impella device lowers LVEDP in the setting of 
increased afterload due to the presence of the V-A ECMO outflow catheter in the 
aorta.2 Our patient required full circulatory support with V-A ECMO due to 
vasodilatory, distributive shock after protamine during CABG, which resulted in 
circulatory collapse. On the platform of V-A ECMO, the addition of an Impella 
device to reduce ventricular loading results in improved survival and recovery of 
ventricular performance in the setting of CS.2 However, there is an increased risk 
of complications related to the thrombogenic nature of MCS devices in the LV. The 
risk of cerebrovascular accidents in such patients are reported to be as high as 
10%.2,4 In the case of our patient, several factors, such as decreased flow due to 
CS, a severely akinetic apical segment, and multiple MCS devices, led to an 
overall increased risk for thrombotic events. Management strategies for patients 
with femoral V-A ECMO support and severely impaired LV function must be 
reassessed to avoid insufficient LV unloading at an early stage of ECMO therapy. 
Adjusting the flow rate of ECMO and Impella, as well as ionotropic support and 
diuresis should be considered in patients with insufficient unloading of the LV to 
prevent intra-cardiac thrombus formation and reduce LV distention. Despite all 
these measures, our patient had thrombotic complications. 
The SCPS is FDA-approved and indicated for use during TAVR procedures to 
protect against embolic events.5,6 Herein, we demonstrate the application of this 
device in a relatively unique clinical dilemma. We understand its use in our 
scenario may not eradicate cerebral embolic events; however, we believe it 
provided an overall clinical benefit to our patient compared to the potential 
ramifications of Impella removal without SCPS. Therefore, the use of SPCS during 
MCS removal, such as Impella, in patients with an intra-cardiac thrombus may be 
a future indication for this device. Further investigation is necessary to understand 
the applicability to the general population prior to its widespread use. 
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Conclusion 
As the utilization of percutaneous MCS continues to increase, related 
complications will need to be carefully monitored. A multi-disciplinary approach, 
including interventional cardiologists, heart failure subspecialists and 
cardiovascular surgeons, will be crucial in managing such events. Current 
conventional options, such as the SCPS to prevent cerebral embolic events, as 
well as other emerging therapies will need to be adapted to address these issues 
going forward.  
 
References 
1. Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS clinical 
expert consensus statement on the use of percutaneous mechanical 
circulatory support devices in cardiovascular care: endorsed by the American 
Heart Association, the Cardiological Society of India, and Sociedad Latino 
Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian 
Association of Interventional Cardiology-Association Canadienne de 
Cardiologie d'intervention. J Am Coll Cardiol. 2015;65(19):e7-e26  
2. Patel SM, Lipinski J, Al-Kindi SG, et al. Simultaneous venoarterial 
extracorporeal membrane oxygenation and percutaneous left ventricular 
decompression therapy with Impella is associated with improved outcomes in 
refractory cardiogenic shock. ASAIO J. 2019;65(1):21-28. 
3. Weber C, Deppe AC, Sabashnikov A, et al. Left ventricular thrombus formation 
in patients undergoing femoral veno-arterial extracorporealmembrane 
oxygenation. Perfusion. 2018;33(4):283-288. 
4. Nguyen D, Ellison D, Ngo C, Steinberg Z, Don C, Cheng RK. Intraventricular 
Free-Floating Thrombus in an Impella-Supported Patient: Damage Control in a 
No-Win Scenario. J Am Coll Cardiol Case Rep. 2020;2(6):886-888.  
5. Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral embolism 
during transcatheter aortic valve replacement. J Am Coll Cardiol. 
2017;69(4):367-377. 
6. Sachedina AK, Ajluni SC, Jumean MF. The use of a sentinel cerebral 
protection system during Impella CP removal in a patient with left ventricular 
thrombus. Catheter Cardiovasc Interv. 2020;96(2):504-506.  
